Advances in Biopharmaceutical Technology in India
back to index


Chapter 1:   Prospects for Modern Biotechnology in India

Throughout its history, the Indian government has created policies to help enable the manufacturing of conventional and modern biotech products at affordable prices. Presently, private companies in India dominate the biomanufacturing sector, while new and existing institutes are being created and funded by the government. To educate and train future workers, biotech courses are being offered at graduate, postgraduate, and Ph.D. levels; private institutions are also supporting these efforts. The Indian government is working to create an alliance between private industry and research institutes. With the help of local governments, biotech parks are being created to assist small and medium level enterprises with startup funds. With private companies investing little for research and development, alliances between private industry and institutes for basic research has been small, even with help from the Indian government. However, in the next decade, with collaboration from the Indian government and private companies, there should be a significant increase in the development of conventional biotech industry, and modern biotech drugs may be produced once Intellectual Property Rights (IPR) expire.

About the Authors:

Prasanta K. Ghosh
President, Biotechnology, Cadila Pharmaceuticals Ltd.
North Gujarat, India

Prasenjeet Ghosh, Senior Scientist, Exxon Mobil Research and Engineering, New Jersey, U.S.
Soma Ghosh, Management Trainee, Cadila Pharmaceuticals Ltd.
Kushal Shodhan, Manager, Biotechnology, Cadila Pharmaceuticals Ltd.

Prasanta K. Ghosh, PhD, FIE, C. Chem, FRSC, received his Master of Technology in chemical engineering and a Ph.D., University of Calcutta, and has worked in various government departments since the late 1960s. Actively involved in policy-making for the production & pricing of drugs and pharmaceuticals, he also developed biotech policies relating to industrial development, IPR protection in publicly funded institutions, technology transfer and policies relating to use of genetically-modified organisms. With hands-on experience in the production of antibiotics, sera and vaccines respectively, fermentation, handling of blood & blood products and separation of biomolecules using various separation techniques, his primary research interest is in the production of hydrophilic polymeric nanoparticles made up of synthetic as well as natural polymers. He heads the biotech division for Cadila Pharmaceuticals Ltd., Ahmedabad, India, and has more than 80 publications to his credit, including several U.S. Patents.

Prasenjeet Ghosh received his Bachelor of Technology in chemical engineering from the Indian Institute of Technology, Roorkee (India) and Ph.D. from Purdue University, U.S. After the completion of his graduate degree in India he worked in fermentation-based industries as a trainee. Presently he is working as a Senior Scientist for Exxon Mobil Research and Engineering (U.S.), and is pursuing an MBA at Wharton University (U.S.)

Soma Ghosh received her M.Sc. in Zoology and an M. Phil from the University of Delhi. She has undergone training in biotech industry, working with Cadila Pharmaceuticals Ltd. during her studies, and has an interest in understanding the global biotech industry in depth. Trained in molecular and cellular biology, she currently works for Cadila Pharmaceuticals Ltd. as a scientist.

Kushal Shodhan received her M. Sc. from Sardar Patel University, India, and is currently working on her M.S.(Thesis) in Biochemistry from Stevens Institute of Technology (U.S.) As a manager of R&D Biotechnology for Cadila Pharmaceuticals Ltd., India, she works in the field of extraction, purification and modification of natural polymers, understanding their medical uses and preparation of nanoparticles.

back to index
Eric Langer
BioPlan Associates, Inc.
2275 Research Blvd, Suite 500
Rockville, MD 20850
Phone: 301-921-5979; Fax: 301-926-2455